GDP to contract 8.6% in Q2; India has entered recession for first time, says RBI official

Researchers have used the 'nowcasting' method to arrive at the estimates ahead of the official release of data and their views in an article in RBI's monthly bulletin released on Wednesday do not constitute the central bank's views

Press Trust of India November 11, 2020 23:32:48 IST
GDP to contract 8.6% in Q2; India has entered recession for first time, says RBI official

India economy. Reuters

Mumbai: The GDP is likely to contract by 8.6 percent for the July-September period, which means India will enter into a recession for the first time in history in the first half of this fiscal with two successive quarters of negative growth due to the COVID-19 pandemic, as per an RBI official.

Researchers have used the 'nowcasting' method to arrive at the estimates ahead of the official release of data and their views in an article in RBI's monthly bulletin released on Wednesday do not constitute the central bank's views.

The pandemic-induced lockdowns had led to a steep contraction of 23.9 percent in the GDP for the April-June quarter as compared to the same period a year ago.

The RBI has estimated that the economy will contract by 9.5 percent for the full fiscal year.

"India has entered a technical recession in the first half of 2020-21 for the first time in its history with Q2 2020-21 likely to record the second successive quarter of GDP contraction," as per the article titled 'Economic Activity Index', authored by Pankaj Kumar of the Monetary Policy Department.

It, however, added that the contraction is "ebbing with gradual normalisation in activities and expected to be short-lived."

The index is constructed from 27 monthly indicators using a dynamic factor model and suggests that the economy rebounded sharply from May/June 2020 with the reopening of the economy, with industry normalising faster than contact-intensive service sectors, it said.

The economic activity index can be used to gauge directional movements in GDP growth well ahead of official releases, it said.

The official GDP data will be released later this month.

The article said despite the raging pandemic, preliminary estimates are showing a jump in household financial savings to 21.4 percent of GDP for the June quarter, as against 7.9 percent in the June 2019 quarter and 10 percent in the immediately preceding March 2020 quarter.

"The sharp increase is counter-seasonal and may be attributed to the COVID 19-led reduction in discretionary expenditure or the associated forced saving and the surge in precautionary saving despite stagnant/reduced income," it said.

The estimated increase in financial savings looks consistent with other macroeconomic statistics, in particular the decline in private final consumption expenditure and the surplus position in the external current account, it said.

The "yawning gap" between credit extended and deposits mobilised during the April-June period contributed to the spike in household financial savings as the financial instruments relating to banks continue to dominate the household financial assets and liabilities, it said.

Updated Date:

also read

'This is one to watch': WHO hosts special meeting on worrying new COVID-19 variant
World

'This is one to watch': WHO hosts special meeting on worrying new COVID-19 variant

The WHO could decide if it's a 'variant of concern' — the most worrying type, like the well-known delta variant — or a 'variant of interest,' and whether to use a Greek letter to classify it

'The situation is dramatically serious': German air force to move ICU patients as COVID-19 cases rise
World

'The situation is dramatically serious': German air force to move ICU patients as COVID-19 cases rise

Health Minister Jens Spahn said Germany was having to organise large-scale transfers of patients within the country for the first time since the outbreak began in early 2020

ITC begins clinical trials of nasal spray for COVID-19 prevention
science

ITC begins clinical trials of nasal spray for COVID-19 prevention

The company has received approvals from ethics committees and is registered with CTRI for clinical trials of the nasal spray, which is designed to arrest the virus at the entry point in the nasal cavity